retatrutide clinical trials phase Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and Lilly's triple agonist, retatrutide, delivered

For some, staying at 8mg represents the best balance of efficacy and tolerability

MOTS-C levels in humans decline by approximately 21% between ages 30 and 80

Emerging evidence suggests benefits in alcohol use disorder, smoking cessation, asthma, psoriasis, inflammatory bowel disease, depression, food cravings, binge-eating behaviour, and potentially even neurodegenerative disease

4 Discussion Compared with RG group, more reductions of Scr, BUN, UA, and better improvement of eGFR were observed in RG + CHF group

The #uncomfortable #truth This 2026 BMJ systematic review and #metaanalysis delivers one of the clearest reality checks yet on weight regain after stopping weight-management medications (WMMs), including GLP-1 and dual incretin therapies